Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6960577 | CHEPLAPHARM | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-591) | Mar 19, 2012 |
New Patient Population(NPP) | Dec 04, 2012 |
Pediatric Exclusivity(PED) | Jun 04, 2013 |
Market Authorisation Date: 30 September, 1996
Treatment: Prozac and olanzapine in combination for the acute treatment of treatment resistant depression in adults
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6960577 | CHEPLAPHARM | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-591) | Mar 19, 2012 |
Pediatric Exclusivity(PED) | Jun 04, 2013 |
New Patient Population(NPP) | Dec 04, 2012 |
Market Authorisation Date: 06 April, 2000
Treatment: Zyprexa zydis and fluoxetine in combination for the acute treatment of treatment resistant depression in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL